Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 3229

Sort by

Sort Order Select

Journal Articles

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu, Irit Avivi, Anat Aharon, Gabi Shefer, Shai Levi, Yotam Bronstein, Miguel Morales, Tomer Ziv, Yamit Shorer Arbel, Lydia Scarfò, Erel Joffe, Chava Perry, Paolo Ghia

Blood (2021) 137 (23): 3165–3173.

https://doi.org/10.1182/blood.2021011568

Published: 2021

Includes: Supplemental data

Journal Articles

Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia

Naranie Shanmuganathan, Ilaria S. Pagani, David M. Ross, Sahee Park, Agnes S. M. Yong, Jodi A. Braley, Haley K. Altamura, Devendra K. Hiwase, David T. Yeung, Dong-Wook Kim, Susan Branford, Timothy P. Hughes

Blood (2021) 137 (9): 1196–1207.

https://doi.org/10.1182/blood.2020005514

Published: 2021

Includes: Supplemental data

Journal Articles

Should I rock the boat? When to stop TKIs in CML

Aziz Nazha

Blood (2021) 137 (9): 1136–1137.

https://doi.org/10.1182/blood.2020008645

Published: 2021

Journal Articles

The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML

Blood (2020) 136 (5): 596–609.

https://doi.org/10.1182/blood.2019003636

Published: 2020

Includes: Supplemental data

Journal Articles

An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia

Blood (2020) 135 (26): 2337–2353.

https://doi.org/10.1182/blood.2020004834

Published: 2020

Includes: Supplemental data

Journal Articles

CML: new tools to answer old questions

George Giotopoulos, Brian J. P. Huntly

Blood (2020) 135 (26): 2327–2328.

https://doi.org/10.1182/blood.2020005599

Published: 2020

Journal Articles

Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs

Marco De Dominici, Patrizia Porazzi, Youcai Xiao, Allen Chao, Hsin-Yao Tang, Gaurav Kumar, Paolo Fortina, Orietta Spinelli, Alessandro Rambaldi, Luke F. Peterson, Svetlana Petruk, Camilla Barletta, Alexander Mazo, Gino Cingolani, Joseph M. Salvino, Bruno Calabretta

Blood (2020) 135 (18): 1560–1573.

https://doi.org/10.1182/blood.2019003604

Published: 2020

Includes: Supplemental data

Journal Articles

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD + acute myeloid leukemia

Blood (2020) 135 (17): 1472–1483.

https://doi.org/10.1182/blood.2019003538

Published: 2020

Includes: Supplemental data

Journal Articles

Molecular monitoring during dose reduction predicts recurrence after TKI cessation in CML

Andrea Gottschalk, Ingmar Glauche, Silvia Cicconi, Richard E. Clark, Ingo Roeder

Blood (2020) 135 (10): 766–769.

https://doi.org/10.1182/blood.2019003395

Published: 2020

Includes: Supplemental data

Journal Articles

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

Simona Soverini, Luana Bavaro, Caterina De Benedittis, Margherita Martelli, Alessandra Iurlo, Nicola Orofino, Simona Sica, Federica Sorà, Francesca Lunghi, Fabio Ciceri, Sara Galimberti, Claudia Baratè, Massimiliano Bonifacio, Luigi Scaffidi, Fausto Castagnetti, Gabriele Gugliotta, Francesco Albano, Antonella Vita Russo Rossi, Fabio Stagno, Francesco di Raimondo, Mariella D’Adda, Eros di Bona, Elisabetta Abruzzese, Gianni Binotto, Rosaria Sancetta, Marzia Salvucci, Isabella Capodanno, Mariella Girasoli, Sabrina Coluzzi, Immacolata Attolico, Caterina Musolino, Elisabetta Calistri, Mario Annunziata, Monica Bocchia, Stefania Stella, Anna Serra, Santa Errichiello, Giuseppe Saglio, Fabrizio Pane, Paolo Vigneri, Flavio Mignone, Maria Antonella Laginestra, Stefano Aldo Pileri, Antonio Percesepe, Elena Tenti, Gianantonio Rosti, Michele Baccarani, Michele Cavo, Giovanni Martinelli

Blood (2020) 135 (8): 534–541.

https://doi.org/10.1182/blood.2019002969

Published: 2020

Includes: Supplemental data

Journal Articles

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Blood (2019) 134 (23): 2036–2045.

https://doi.org/10.1182/blood.2019000069

Published: 2019

Includes: Supplemental data

Journal Articles

Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations

Jennifer Woyach, MD, Ying Huang, MS, MA, Kerry Rogers, Seema A. Bhat, MD, Michael R. Grever, MD, Arletta Lozanski, Tzyy-Jye Doong, James S. Blachly, MD, Gerard Lozanski, MD, Dan Jones, MD PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 504.

https://doi.org/10.1182/blood-2019-127674

Published: 2019

Journal Articles

Incidence of High-Grade Hematologic Toxicities and Hypertension in Patients with Hematological Malignancies Treated with Ibrutinib

Chandler Graf, Anita Sultan, MD, Donald P. Quick, MD, Bradley J. Grant, JD, Sriman Swarup, MDMBBS, Thura Win Htut, MBBS, MRCP, Pwint Phyu Hlaing, MD, Myat Min Han, MD, Yin Mon Myat, MD, Fred Hardwicke, MD, Sanjay Awasthi, MD, Nicholas D'Cunha, MD, Lukman Tijani, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5876.

https://doi.org/10.1182/blood-2019-123297

Published: 2019

Journal Articles

On a Long Way to the Treatment Free Remisson: The Results of the Long-Term Observation of the Chronic Myeloid Leukemia Patients in Russian Part of EUTOS Population-Based Study

Olga V. Lazareva, PhD, Ekaterina Yu. Chelysheva, MD PhD, Anton Kulikovsky, Olga Senderova, Valentina Pepeliaeva, Sergey Meresiy, Alexander S. Luchinin, MD, Galina Milutina, Lubov Gavrilova, Ludmila Avdeeva, Dolgorzhap Dasheeva, Olga Vinogradova, MD PhD, Sergei M. Kulikov, PhD, Anna G. Turkina, Prof., MD

Blood (2019) 134 (Supplement_1): 5902.

https://doi.org/10.1182/blood-2019-131430

Published: 2019

Journal Articles

Combination of Gatekeeper Mutations and Cysteine 481 Replacement Causes Super Resistance to the Irreversible BTK Inhibitors Ibrutinib, Acalabrutinib and Zanubrutinib

Hernando Yesid Estupiñan Velasquez, Yuye Shi, MD PhD, Dara K. Mohammad, PhD, Qing Wang, Mauno Vihinen, PhD, Rula Zain, PhD, Anna Berglöf, PhD VMD, Edvard CI Smith, MD PhD

Blood (2019) 134 (Supplement_1): 5759.

https://doi.org/10.1182/blood-2019-123398

Published: 2019

Journal Articles

Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Effect of a One-Year Consolidation Treatment with Ponatinib 15 Mg on Treatment Free-Remission Rate in Patients with Philadelphia-Positive Chronic Myeloid Leukemia, Who Had Previously Achieved a Deep Molecular Response with Imatinib (PonaZero_study)

Valentin Garcia Gutierrez, MD PhD, Luis Felipe Casado, Rosa Ayala, MD PhD, Fermin Sanchez-Guijo, MD PhD, Juan Carlos Hernandez Boluda, María Teresa Gomez Casares, Blanca Xicoy, MD MSc, Begonya Maestro, PhD, Juan Luis Steegmann, Arturo Garcia de Diego

Blood (2019) 134 (Supplement_1): 5904.

https://doi.org/10.1182/blood-2019-125627

Published: 2019

Journal Articles

Ponatinib Treatment in CML and Ph+ ALL Patients: Real-Life Data from the Czech Registries

Eva Koriťáková, RNDr., PhD, Michael Doubek, MD PhD, Edgar Faber, MD PhD, Daniela Žáčková, MD PhD, Jan M. Horáček, MD PhD, Petra Bělohlávková, MD PhD, Eduard Cmunt, MD PhD, František Folber, MD PhD, Pavel Jindra, MD PhD, Hana Klamová, MD PhD, Zdeněk Kořístek, MD PhD, Lukáš Stejskal, MD, Tomáš Szotkowski, MD PhD, Cyril Šálek, MD PhD, Renata Kellnerová, MD PhD, Marika Chrápavá, Mgr.

Blood (2019) 134 (Supplement_1): 5905.

https://doi.org/10.1182/blood-2019-126395

Published: 2019

Journal Articles

Systematic Literature Review on Global Real-World Treatment Patterns of Mantle Cell Lymphoma (MCL)

Keri Keri Yang, Beth Lesher, PharmD, Eleanor Lucas, BA, Tony Caver, PhD, Boxiong Tang, MD PhD

Blood (2019) 134 (Supplement_1): 5881.

https://doi.org/10.1182/blood-2019-130896

Published: 2019

Journal Articles

A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib

Veronica A Guerra, MD, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Srdan Verstovsek, MD PhD, Allison Pike, RN, Farhad Ravandi, MD, Elias Jabbour, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 5906.

https://doi.org/10.1182/blood-2019-127272

Published: 2019

Journal Articles

Effects of Ramadan Fasting in Patients with Chronic Myeloid Leukemia in Chronic Phase

Mohamed A Yassin, MBBS, MSc, Rola S Ghasoub, BSC, Mahmood B Aldapt, MD, Mohammad Abdul-Jaber Abdulla, MD, Prem Chandra, PhD, Hawraa M Shwaylia, MD, Abdulqadir Jeprel Nashwan, BSN, MSN, Nancy Kassem, BSC, Susanna Jane Akiki, PhD

Blood (2019) 134 (Supplement_1): 5907.

https://doi.org/10.1182/blood-2019-121827

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia

Should I rock the boat? When to stop TKIs in CML

The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML

An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia

CML: new tools to answer old questions

Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD + acute myeloid leukemia

Molecular monitoring during dose reduction predicts recurrence after TKI cessation in CML

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations

Incidence of High-Grade Hematologic Toxicities and Hypertension in Patients with Hematological Malignancies Treated with Ibrutinib

On a Long Way to the Treatment Free Remisson: The Results of the Long-Term Observation of the Chronic Myeloid Leukemia Patients in Russian Part of EUTOS Population-Based Study

Combination of Gatekeeper Mutations and Cysteine 481 Replacement Causes Super Resistance to the Irreversible BTK Inhibitors Ibrutinib, Acalabrutinib and Zanubrutinib

Ponatinib Treatment in CML and Ph+ ALL Patients: Real-Life Data from the Czech Registries

Systematic Literature Review on Global Real-World Treatment Patterns of Mantle Cell Lymphoma (MCL)

A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib

Effects of Ramadan Fasting in Patients with Chronic Myeloid Leukemia in Chronic Phase

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only